US FDA Cancer Office Keeps Hemorrhaging Staff, Most Land At Industry

 
• By Sarah Karlin-Smith
  
people exiting office building with revolving doors
The large proportion of cancer staff who have recently left the FDA to join industry may prompt a reexamination of the relationship between the agency and pharma. (Shutterstock)

More from US FDA

More from Pink Sheet